Evolus narrowed its 2024 guidance range, reflecting improved visibility with one quarter left. CEO and CFO are confident in meeting targets despite market fluctuations. The toxin market shows resilience, with Evolus expecting strong growth and consumer engagement.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing